Experimental cell shot aims to tame Out-of-Control nerve attacks
NCT ID NCT07275736
First seen Dec 12, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-phase study tests a new cell therapy called CNCT19 in 18 adults with severe autoimmune nerve diseases that have not responded to standard treatments. The therapy targets and removes certain immune cells (CD19+ B cells) that are attacking the nervous system. The main goals are to check safety and see if it can reduce relapses and disability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.